LEAPs is on the back-burner while the more advanced Multikine gets put through its paces,... but it never hurts to have some secondary product pipeline in place that can be activated once the company is more certain that the Multikine trials are going smoothly.
The big advantage with LEAPs - relative to Multikine - is that trails for effacy against a short-cycle disease like flu viruses are less expensive to run (mostly due to the short time frame) and flu patients can be very abundant if the company is ready to go when flu season is rolling along.
So - once the Multikine study is winding down, it should be easy enough to get the Phase I and Phase II aspects of LEAPs set up.
One thing at a time though folks - companies with limited operating budget have to be careful not to overstretch their resources - and CVM is already maxed out.
News 
Market Data 
Discover 
